Updated:
Syntheon
Syntheon invents medical devices and sells the IP to strategics — 200+ patents, $6B in downstream sales, and a 2023 Medtronic acquisition headline the...
Syntheon
Syntheon operates from five US offices as a closely held device incubator that invents, develops, and patents surgical tools and cardiac implants before selling intellectual property to established manufacturers. The firm’s website names partnerships with Boston Scientific, Johnson & Johnson's Ethicon unit, Edwards Lifesciences, Medtronic, and Covidien, and claims more than 52 million patients have been treated with devices originating from its labs. The model does not scale through AUM — it monetizes through outright acquisitions of individual device technologies. The firm’s output spans multiple surgical specialties. Confirmed exits include Medtronic’s acquisition of the Penditure Left Atrial Appendage Exclusion System in August 2023 (per firm website, 2023), an implantable clip used during concomitant cardiac surgery. Syntheon also lists Edwards Lifesciences as a partner, pointing toward structural heart valve or hemodynamic monitoring device collaborations. The company’s product breadth reaches across cardiovascular, endosurgery, and general minimally invasive platforms, backed by a portfolio of more than 200 patents. Syntheon does not disclose headcount or capital under management. In August 2023, Medtronic completed the acquisition of Syntheon's Penditure LAA clip technology, adding left atrial appendage management to Medtronic's Cardiac Surgery portfolio. The firm maintains a co-location model with engineering and commercial teams distributed across Miami, Durham, Boston, Austin, and Bethesda. Philanthropic or adjacent club-vehicle structures are not publicly documented. The incubator structure is itself the edge: Syntheon carries no ongoing portfolio to mark, but generates liquidity event by event through clean asset sales to strategics. Unlike a venture-backed device startup, Syntheon shoulders the full cost of invention and de-risks the clinical concept before a buyer ever touches it, a capital-intensive posture that demands deep pockets and a willingness to be paid on the other side of FDA clearance or first-in-human data.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Miami
Corporate office
13755 SW 119th Ave, Miami, FL 33186, United States
Additional offices
Durham, NC · Boston, MA · Austin, TX · Bethesda, MD
Sector focus
Frequently asked questions
How does Syntheon generate returns if it is not a traditional fund?
Syntheon operates as a medical-device incubator, not a pooled investment vehicle. It self-funds the invention, patenting, and early development of electro-mechanical surgical tools and implants, then sells the fully developed intellectual property to large strategics such as Medtronic or Edwards Lifesciences. Returns are realized deal by deal through those acquisitions rather than through management fees or portfolio markups.
Who are Syntheon's known strategic acquirers?
The firm publicly names Boston Scientific, Johnson & Johnson (via Ethicon), Edwards Lifesciences, Medtronic, and Covidien as repeat partners. Medtronic's August 2023 acquisition of the Penditure Left Atrial Appendage Exclusion System is the most recent publicly confirmed transaction.
What kinds of medical devices does Syntheon build?
Syntheon focuses on complex electro-mechanical devices for minimally invasive surgery and cardiac care. Confirmed categories include left atrial appendage management clips, and the firm's broader partnership footprint with Edwards Lifesciences and Ethicon suggests work in structural heart, suturing, and endosurgical instrumentation.
Does Syntheon take outside capital or co-invest alongside venture firms?
There is no public evidence Syntheon raises external funds or syndicates with venture capital firms. The model appears self-financed, with principals carrying the full development risk in exchange for retaining all intellectual property until a strategic sale.
How is Syntheon's intellectual property protected before a sale?
The firm holds more than 200 patents and emphasizes early-stage engineering de-risking. By the time a technology is offered to a strategic buyer, Syntheon typically has a patent estate, functioning prototypes, and often early clinical or human-factors data, which shifts FDA and commercial risk to the acquirer post-sale.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: